SARS-CoV Infections in Humans

Human Respiratory Viral Infections

Volumn , Issue , 2014, Pages 559-582

  To, K F ^a   Lo, Anthony W I ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84982699216     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1201/b16778-28     Document Type: Chapter

References (209)

1. van der Hoek L. Human coronaviruses: What do they cause? Antivir Ther. 2007; 12(4 Pt B): 651-658.
2. Drosten C, Gunther S, Preiser W, van der Werf S, Brodt HR, Becker S et al. Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N Engl J Med. 2003; 348(20): 1967-1976.
3. Ding Y, Wang H, Shen H, Li Z, Geng J, Han H et al. The clinical pathology of severe acute respiratory syndrome (SARS): A report from China. J Pathol. 2003; 200(3): 282-289.
4. Ksiazek TG, Erdman D, Goldsmith CS, Zaki SR, Peret T, Emery S et al. A novel coronavirus associated with severe acute respiratory syndrome. N Engl J Med. 2003; 348(20): 1953-1966.
5. Kuiken T, Fouchier RA, Schutten M, Rimmelzwaan GF, van Amerongen G, van Riel D et al. Newly discovered coronavirus as the primary cause of severe acute respiratory syndrome. Lancet. 2003; 362(9380): 263-270.
6. Nicholls JM, Poon LL, Lee KC, Ng WF, Lai ST, Leung CY et al. Lung pathology of fatal severe acute respiratory syndrome. Lancet. 2003; 361(9371): 1773-1778.
7. Cheung OY, Chan JW, Ng CK, Koo CK. The spectrum of pathological changes in severe acute respiratory syndrome (SARS). Histopathology. 2004; 45(2): 119-124.
8. Goldsmith CS, Tatti KM, Ksiazek TG, Rollin PE, Comer JA, Lee WW et al. Ultrastructural characterization of SARS coronavirus. Emerg Infect Dis. 2004; 10(2): 320-326.
9. Xu D, Zhang Z, Wang FS. SARS-associated coronavirus quasispecies in individual patients. N Engl J Med. 2004; 350(13): 1366-1367.
10. Chim SS, Tsui SK, Chan KC, Au TC, Hung EC, Tong YK et al. Genomic characterisation of the severe acute respiratory syndrome coronavirus of Amoy Gardens outbreak in Hong Kong. Lancet. 2003; 362(9398): 1807-1808.
11. Guan Y, Zheng BJ, He YQ, Liu XL, Zhuang ZX, Cheung CL et al. Isolation and characterization of viruses related to the SARS coronavirus from animals in southern China. Science. 2003; 302(5643): 276-278.
12. Thiel V, Ivanov KA, Putics A, Hertzig T, Schelle B, Bayer S et al. Mechanisms and enzymes involved in SARS coronavirus genome expression. J Gen Virol. 2003; 84(Pt 9): 2305-2315.
13. Snijder EJ, Bredenbeek PJ, Dobbe JC, Thiel V, Ziebuhr J, Poon LL et al. Unique and conserved features of genome and proteome of SARS-coronavirus, an early split-off from the coronavirus group 2 lineage. J Mol Biol. 2003; 331(5): 991-1004.
14. Eickmann M, Becker S, Klenk HD, Doerr HW, Stadler K, Censini S et al. Phylogeny of the SARS coronavirus. Science. 2003; 302(5650): 1504-1505.
15. Hu J, Wang J, Xu J, Li W, Han Y, Li Y et al. Evolution and variation of the SARS-CoV genome. Genom Proteom Bioinform. 2003; 1(3): 216-225.
16. Ruan YJ, Wei CL, Ee AL, Vega VB, Thoreau H, Su ST et al. Comparative full-length genome sequence analysis of 14 SARS coronavirus isolates and common mutations associated with putative origins of infection. Lancet. 2003; 361(9371): 1779-1785.
17. Zeng F, Chow KY, Leung FC. Estimated timing of the last common ancestor of the SARS coronavirus. N Engl J Med. 2003; 349(25): 2469-2470.
18. Gibbs AJ, Gibbs MJ, Armstrong JS. The phylogeny of SARS coronavirus. Arch Virol. 2004; 149(3): 621-624.
19. Holmes EC, Rambaut A. Viral evolution and the emergence of SARS coronavirus. Philos Trans R Soc Lond B Biol Sci. 2004; 359(1447): 1059-1065.
20. Lio P, Goldman N. Phylogenomics and bioinformatics of SARS-CoV. Trends Microbiol. 2004; 12(3): 106-111.
21. Pavlovic-Lazetic GM, Mitic NS, Beljanski MV. Bioinformatics analysis of SARS coronavirus genome polymorphism. BMC Bioinform. 2004; 5: 65.
22. Lan YC, Liu HF, Shih YP, Yang JY, Chen HY, Chen YM. Phylogenetic analysis and sequence comparisons of structural and non-structural SARS coronavirus proteins in Taiwan. Infect Genet Evol. 2005; 5(3): 261-269.
23. Bolles M, Donaldson E, Baric R. SARS-CoV and emergent coronaviruses: Viral determinants of interspecies transmission. Curr Opin Virol. 2011; 1(6): 624-634.
24. Anand K, Ziebuhr J, Wadhwani P, Mesters JR, Hilgenfeld R. Coronavirus main proteinase (3CLpro) structure: Basis for design of anti-SARS drugs. Science. 2003; 300(5626): 1763-1767.
25. Brian DA, Baric RS. Coronavirus genome structure and replication. Curr Top Microbiol Immunol. 2005; 287: 1-30.
26. Hussain S, Pan J, Xu J, Yang Y, Chen Y, Peng Y et al. Identification and characterization of severe acute respiratory syndrome coronavirus subgenomic RNAs. Adv Exp Med Biol. 2006; 581: 85-88.
27. Masters PS. The molecular biology of coronaviruses. Adv Virus Res. 2006; 66: 193-292.
28. Xu J, Hu J, Wang J, Han Y, Hu Y, Wen J et al. Genome organization of the SARS-CoV. Genom Proteom Bioinform. 2003; 1(3): 226-235.
29. Hussain S, Pan J, Chen Y, Yang Y, Xu J, Peng Y et al. Identification of novel subgenomic RNAs and noncanonical transcription initiation signals of severe acute respiratory syndrome coronavirus. J Virol. 2005; 79(9): 5288-5295.
30. Gao F, Ou HY, Chen LL, Zheng WX, Zhang CT. Prediction of proteinase cleavage sites in polyproteins of coronaviruses and its applications in analyzing SARS-CoV genomes. FEBS Lett. 2003; 553(3): 451-456.
31. Barretto N, Jukneliene D, Ratia K, Chen Z, Mesecar AD, Baker SC. The papain-like protease of severe acute respiratory syndrome coronavirus has deubiquitinating activity. J Virol. 2005; 79(24): 15189-15198.
32. Han YS, Chang GG, Juo CG, Lee HJ, Yeh SH, Hsu JT et al. Papain-like protease 2 (PLP2) from severe acute respiratory syndrome coronavirus (SARS-CoV): Expression, purification, characterization, and inhibition. Biochemistry. 2005; 44(30): 10349-10359.
33. Lindner HA, Fotouhi-Ardakani N, Lytvyn V, Lachance P, Sulea T, Menard R. The papain-like protease from the severe acute respiratory syndrome coronavirus is a deubiquitinating enzyme. J Virol. 2005; 79(24): 15199-15208.
34. De Clercq E. Potential antivirals and antiviral strategies against SARS coronavirus infections. Expert Rev Anti Infect Ther. 2006; 4(2): 291-302.
35. Ratia K, Saikatendu KS, Santarsiero BD, Barretto N, Baker SC, Stevens RC et al. Severe acute respiratory syndrome coronavirus papain-like protease: Structure of a viral deubiquitinating enzyme. Proc Natl Acad Sci USA. 2006; 103(15): 5717-5722.
36. Wu YS, Lin WH, Hsu JT, Hsieh HP. Antiviral drug discovery against SARS-CoV. Curr Med Chem. 2006; 13(17): 2003-2020.
37. Frieman M, Ratia K, Johnston RE, Mesecar AD, Baric RS. Severe acute respiratory syndrome coronavirus papain-like protease ubiquitin-like domain and catalytic domain regulate antagonism of IRF3 and NF-kappaB signaling. J Virol. 2009; 83(13): 6689-6705.
38. Ghosh AK, Takayama J, Rao KV, Ratia K, Chaudhuri R, Mulhearn DC et al. Severe acute respiratory syndrome coronavirus papain-like novel protease inhibitors: Design, synthesis, protein-ligand X-ray structure and biological evaluation. J Med Chem. 2010; 53(13): 4968-4979.
39. Liang PH. Characterization and inhibition of SARS-coronavirus main protease. Curr Top Med Chem. 2006; 6(4): 361-376.
40. Feng Y, Gao GF. Towards our understanding of SARS-CoV, an emerging and devastating but quickly conquered virus. Comp Immunol Microbiol Infect Dis. 2007; 30(5-6): 309-327.
41. Egloff MP, Ferron F, Campanacci V, Longhi S, Rancurel C, Dutartre H et al. The severe acute respiratory syndrome-coronavirus replicative protein nsp9 is a single-stranded RNA-binding subunit unique in the RNA virus world. Proc Natl Acad Sci USA. 2004; 101(11): 3792-3796.
42. Sutton G, Fry E, Carter L, Sainsbury S, Walter T, Nettleship J et al. The nsp9 replicase protein of SARS-coronavirus, structure and functional insights. Structure. 2004; 12(2): 341-353.
43. Ivanov KA, Thiel V, Dobbe JC, van der Meer Y, Snijder EJ, Ziebuhr J. Multiple enzymatic activities associated with severe acute respiratory syndrome coronavirus helicase. J Virol. 2004; 78(11): 5619-5632.
44. Ziebuhr J. The coronavirus replicase: Insights into a sophisticated enzyme machinery. Adv Exp Med Biol. 2006; 581: 3-11.
45. Bartlam M, Yang H, Rao Z. Structural insights into SARS coronavirus proteins. Curr Opin Struct Biol. 2005; 15(6): 664-672.
46. Tan YJ, Lim SG, Hong W. Characterization of viral proteins encoded by the SARS-coronavirus genome. Antiviral Res. 2005; 65(2): 69-78.
47. Chen S, Luo H, Chen L, Chen J, Shen J, Zhu W et al. An overall picture of SARS coronavirus (SARS-CoV) genome-encoded major proteins: Structures, functions and drug development. Curr Pharm Des. 2006; 12(35): 4539-4553.
48. Li W, Moore MJ, Vasilieva N, Sui J, Wong SK, Berne MA et al. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature. 2003; 426(6965): 450-454.
49. Hamming I, Timens W, Bulthuis ML, Lely AT, Navis GJ, van Goor H. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J Pathol. 2004; 203(2): 631-637.
50. To KF, Lo AW. Exploring the pathogenesis of severe acute respiratory syndrome (SARS): The tissue distribution of the coronavirus (SARS-CoV) and its putative receptor, angiotensin-converting enzyme 2 (ACE2). J Pathol. 2004; 203(3): 740-743.
51. Belouzard S, Chu VC, Whittaker GR. Activation of the SARS coronavirus spike protein via sequential proteolytic cleavage at two distinct sites. Proc Natl Acad Sci USA. 2009; 106(14): 5871-5876.
52. Simmons G, Bertram S, Glowacka I, Steffen I, Chaipan C, Agudelo J et al. Different host cell proteases activate the SARS-coronavirus spike-protein for cell-cell and virus-cell fusion. Virology. 2011; 413(2): 265-274.
53. Simmons G, Reeves JD, Rennekamp AJ, Amberg SM, Piefer AJ, Bates P. Characterization of severe acute respiratory syndrome-associated coronavirus (SARS-CoV) spike glycoprotein-mediated viral entry. Proc Natl Acad Sci USA. 2004; 101(12): 4240-4245.
54. Simmons G, Rennekamp AJ, Bates P. Proteolysis of SARS-associated coronavirus spike glycoprotein. Adv Exp Med Biol. 2006; 581: 235-240.
55. Bertram S, Glowacka I, Muller MA, Lavender H, Gnirss K, Nehlmeier I et al. Cleavage and activation of the severe acute respiratory syndrome coronavirus spike protein by human airway trypsin-like protease. J Virol. 2011; 85(24): 13363-13372.
56. Kam YW, Okumura Y, Kido H, Ng LF, Bruzzone R, Altmeyer R. Cleavage of the SARS coronavirus spike glycoprotein by airway proteases enhances virus entry into human bronchial epithelial cells in vitro. PLoS One. 2009; 4(11): e7870.
57. He R, Leeson A, Ballantine M, Andonov A, Baker L, Dobie F et al. Characterization of protein-protein interactions between the nucleocapsid protein and membrane protein of the SARS coronavirus. Virus Res. 2004; 105(2): 121-125.
58. Luo H, Wu D, Shen C, Chen K, Shen X, Jiang H. Severe acute respiratory syndrome coronavirus membrane protein interacts with nucleocapsid protein mostly through their carboxyl termini by electrostatic attraction. Int J Biochem Cell Biol. 2006; 38(4): 589-599.
59. Chen SC, Lo SY, Ma HC, Li HC. Expression and membrane integration of SARS-CoV E protein and its interaction with M protein. Virus Genes. 2009; 38(3): 365-371.
60. Yang Y, Xiong Z, Zhang S, Yan Y, Nguyen J, Ng B et al. Bcl-xL inhibits T-cell apoptosis induced by expression of SARS coronavirus E protein in the absence of growth factors. Biochem J. 2005; 392(Pt 1): 135-143.
61. Teoh KT, Siu YL, Chan WL, Schluter MA, Liu CJ, Peiris JS et al. The SARS coronavirus E protein interacts with PALS1 and alters tight junction formation and epithelial morphogenesis. Mol Biol Cell. 2010; 21(22): 3838-3852.
62. Wilson L, Gage P, Ewart G. Hexamethylene amiloride blocks E protein ion channels and inhibits coronavirus replication. Virology. 2006; 353(2): 294-306.
63. Bai B, Hu Q, Hu H, Zhou P, Shi Z, Meng J et al. Virus-like particles of SARS-like coronavirus formed by membrane proteins from different origins demonstrate stimulating activity in human dendritic cells. PLoS One. 2008; 3(7): e2685.
64. Hsieh PK, Chang SC, Huang CC, Lee TT, Hsiao CW, Kou YH et al. Assembly of severe acute respiratory syndrome coronavirus RNA packaging signal into virus-like particles is nucleocapsid dependent. J Virol. 2005; 79(22): 13848-13855.
65. Hsieh YC, Li HC, Chen SC, Lo SY. Interactions between M protein and other structural proteins of severe, acute respiratory syndrome-associated coronavirus. J Biomed Sci. 2008; 15(6): 707-717.
66. Siu KL, Kok KH, Ng MH, Poon VK, Yuen KY, Zheng BJ et al. Severe acute respiratory syndrome coronavirus M protein inhibits type I interferon production by impeding the formation of TRAF3.TANK.TBK1/IKKepsilon complex. J Biol Chem. 2009; 284(24): 16202-16209.
67. Yang L, Peng H, Zhu Z, Li G, Huang Z, Zhao Z et al. Persistent memory CD4+ and CD8+ T-cell responses in recovered severe acute respiratory syndrome (SARS) patients to SARS coronavirus M antigen. J Gen Virol. 2007; 88(Pt 10): 2740-2748.
68. Nakauchi M, Kariwa H, Kon Y, Yoshii K, Maeda A, Takashima I. Analysis of severe acute respiratory syndrome coronavirus structural proteins in virus-like particle assembly. Microbiol Immunol. 2008; 52(12): 625-630.
69. Siu YL, Teoh KT, Lo J, Chan CM, Kien F, Escriou N et al. The M, E, and N structural proteins of the severe acute respiratory syndrome coronavirus are required for efficient assembly, trafficking, and release of virus-like particles. J Virol. 2008; 82(22): 11318-11330.
70. Tseng YT, Wang SM, Huang KJ, Lee AI, Chiang CC, Wang CT. Self-assembly of severe acute respiratory syndrome coronavirus membrane protein. J Biol Chem. 2010; 285(17): 12862-12872.
71. Ying W, Hao Y, Zhang Y, Peng W, Qin E, Cai Y et al. Proteomic analysis on structural proteins of severe acute respiratory syndrome coronavirus. Proteomics. 2004; 4(2): 492-504.
72. Harcourt BH, Jukneliene D, Kanjanahaluethai A, Bechill J, Severson KM, Smith CM et al. Identification of severe acute respiratory syndrome coronavirus replicase products and characterization of papain-like protease activity. J Virol. 2004; 78(24): 13600-13612.
73. Hurst KR, Ye R, Goebel SJ, Jayaraman P, Masters PS. An interaction between the nucleocapsid protein and a component of the replicase-transcriptase complex is crucial for the infectivity of coronavirus genomic RNA. J Virol. 2010; 84(19): 10276-10288.
74. Frieman M, Baric R. Mechanisms of severe acute respiratory syndrome pathogenesis and innate immunomodulation. Microbiol Mol Biol Rev. 2008; 72(4): 672-685, Table of Contents.
75. McBride R, Fielding BC. The role of severe acute respiratory syndrome (SARS)-coronavirus accessory proteins in virus pathogenesis. Viruses. 2012; 4(11): 2902-2923.
76. Narayanan K, Huang C, Makino S. SARS coronavirus accessory proteins. Virus Res. 2008; 133(1): 113-121.
77. Satija N, Lal SK. The molecular biology of SARS coronavirus. Ann N Y Acad Sci. 2007; 1102: 26-38.
78. Weiss SR, Leibowitz JL. Coronavirus pathogenesis. Adv Virus Res. 2011; 81: 85-164.
79. Yu CJ, Chen YC, Hsiao CH, Kuo TC, Chang SC, Lu CY et al. Identification of a novel protein 3a from severe acute respiratory syndrome coronavirus. FEBS Lett. 2004; 565(1-3): 111-116.
80. Yuan X, Li J, Shan Y, Yang Z, Zhao Z, Chen B et al. Subcellular localization and membrane association of SARS-CoV 3a protein. Virus Res. 2005; 109(2): 191-202.
81. Chan WS, Wu C, Chow SC, Cheung T, To KF, Leung WK et al. Coronaviral hypothetical and structural proteins were found in the intestinal surface enterocytes and pneumocytes of severe acute respiratory syndrome (SARS). Mod Pathol. 2005; 18(11): 1432-1439.
82. Qiu M, Shi Y, Guo Z, Chen Z, He R, Chen R et al. Antibody responses to individual proteins of SARS coronavirus and their neutralization activities. Microbes Infect. 2005; 7(5-6): 882-889.
83. Kanzawa N, Nishigaki K, Hayashi T, Ishii Y, Furukawa S, Niiro A et al. Augmentation of chemokine production by severe acute respiratory syndrome coronavirus 3a/X1 and 7a/X4 proteins through NF-kappaB activation. FEBS Lett. 2006; 580(30): 6807-6812.
84. Obitsu S, Ahmed N, Nishitsuji H, Hasegawa A, Nakahama K, Morita I et al. Potential enhancement of osteoclastogenesis by severe acute respiratory syndrome coronavirus 3a/X1 protein. Arch Virol. 2009; 154(9): 1457-1464.
85. Lu B, Tao L, Wang T, Zheng Z, Li B, Chen Z et al. Humoral and cellular immune responses induced by 3a DNA vaccines against severe acute respiratory syndrome (SARS) or SARS-like coronavirus in mice. Clin Vaccine Immunol. 2009; 16(1): 73-77.
86. Padhan K, Minakshi R, Towheed MA, Jameel S. Severe acute respiratory syndrome coronavirus 3a protein activates the mitochondrial death pathway through p38 MAP kinase activation. J Gen Virol. 2008; 89(Pt 8): 1960-1969.
87. Wong SL, Chen Y, Chan CM, Chan CS, Chan PK, Chui YL et al. in vivo functional characterization of the SARS-Coronavirus 3a protein in Drosophila. Biochem Biophys Res Commun. 2005; 337(2): 720-729.
88. Akerstrom S, Mirazimi A, Tan YJ. Inhibition of SARS-CoV replication cycle by small interference RNAs silencing specific SARS proteins, 7a/7b, 3a/3b and S. Antiviral Res. 2007; 73(3): 219-227.
89. Lu W, Zheng BJ, Xu K, Schwarz W, Du L, Wong CK et al. Severe acute respiratory syndrome-associated coronavirus 3a protein forms an ion channel and modulates virus release. Proc Natl Acad Sci USA. 2006; 103(33): 12540-12545.
90. Tan YJ. The Severe Acute Respiratory Syndrome (SARS)-coronavirus 3a protein may function as a modulator of the trafficking properties of the spike protein. Virol J. 2005; 2: 5.
91. Khan S, Fielding BC, Tan TH, Chou CF, Shen S, Lim SG et al. Over-expression of severe acute respiratory syndrome coronavirus 3b protein induces both apoptosis and necrosis in Vero E6 cells. Virus Res. 2006; 122(1-2): 20-27.
92. Yuan X, Shan Y, Yao Z, Li J, Zhao Z, Chen J et al. Mitochondrial location of severe acute respiratory syndrome coronavirus 3b protein. Mol Cells. 2006; 21(2): 186-191.
93. Yuan X, Yao Z, Shan Y, Chen B, Yang Z, Wu J et al. Nucleolar localization of non-structural protein 3b, a protein specifically encoded by the severe acute respiratory syndrome coronavirus. Virus Res. 2005; 114(1-2): 70-79.
94. Varshney B, Agnihothram S, Tan YJ, Baric R, Lal SK. SARS coronavirus 3b accessory protein modulates transcriptional activity of RUNX1b. PLoS One. 2012; 7(1): e29542.
95. Varshney B, Lal SK. SARS-CoV accessory protein 3b induces AP-1 transcriptional activity through activation of JNK and ERK pathways. Biochemistry. 2011; 50(24): 5419-5425.
96. Ye Z, Wong CK, Li P, Xie Y. A SARS-CoV protein, ORF-6, induces caspase-3 mediated, ER stress and JNK-dependent apoptosis. Biochim Biophys Acta. 2008; 1780(12): 1383-1387.
97. Kopecky-Bromberg SA, Martinez-Sobrido L, Frieman M, Baric RA, Palese P. Severe acute respiratory syndrome coronavirus open reading frame (ORF) 3b, ORF 6, and nucleocapsid proteins function as interferon antagonists. J Virol. 2007; 81(2): 548-557.
98. Frieman M, Yount B, Heise M, Kopecky-Bromberg SA, Palese P, Baric RS. Severe acute respiratory syndrome coronavirus ORF6 antagonizes STAT1 function by sequestering nuclear import factors on the rough endoplasmic reticulum/Golgi membrane. J Virol. 2007; 81(18): 9812-9824.
99. Zhao J, Falcon A, Zhou H, Netland J, Enjuanes L, Perez Brena P et al. Severe acute respiratory syndrome coronavirus protein 6 is required for optimal replication. J Virol. 2009; 83(5): 2368-2373.
100. Netland J, Ferraro D, Pewe L, Olivares H, Gallagher T, Perlman S. Enhancement of murine coronavirus replication by severe acute respiratory syndrome coronavirus protein 6 requires the N-terminal hydrophobic region but not C-terminal sorting motifs. J Virol. 2007; 81(20): 11520-11525.
101. Nelson CA, Pekosz A, Lee CA, Diamond MS, Fremont DH. Structure and intracellular targeting of the SARS-coronavirus Orf7a accessory protein. Structure. 2005; 13(1): 75-85.
102. Pekosz A, Schaecher SR, Diamond MS, Fremont DH, Sims AC, Baric RS. Structure, expression, and intracellular localization of the SARS-CoV accessory proteins 7a and 7b. Adv Exp Med Biol. 2006; 581: 115-120.
103. Fielding BC, Tan YJ, Shuo S, Tan TH, Ooi EE, Lim SG et al. Characterization of a unique group-specific protein (U122) of the severe acute respiratory syndrome coronavirus. J Virol. 2004; 78(14): 7311-7318.
104. Tan YJ, Fielding BC, Goh PY, Shen S, Tan TH, Lim SG et al. Overexpression of 7a, a protein specifically encoded by the severe acute respiratory syndrome coronavirus, induces apoptosis via a caspase-dependent pathway. J Virol. 2004; 78(24): 14043-14047.
105. Schaecher SR, Touchette E, Schriewer J, Buller RM, Pekosz A. Severe acute respiratory syndrome coronavirus gene 7 products contribute to virus-induced apoptosis. J Virol. 2007; 81(20): 11054-11068.
106. Zhao K, Yang B, Xu Y, Wu C. CD8+ T cell response in HLA-A*0201 transgenic mice is elicited by epitopes from SARS-CoV S protein. Vaccine. 2010; 28(41): 6666-6674.
107. Tan YX, Tan TH, Lee MJ, Tham PY, Gunalan V, Druce J et al. Induction of apoptosis by the severe acute respiratory syndrome coronavirus 7a protein is dependent on its interaction with the Bcl-XL protein. J Virol. 2007; 81(12): 6346-6355.
108. Kopecky-Bromberg SA, Martinez-Sobrido L, Palese P. 7a protein of severe acute respiratory syndrome coronavirus inhibits cellular protein synthesis and activates p38 mitogen-activated protein kinase. J Virol. 2006; 80(2): 785-793.
109. Vasilenko N, Moshynskyy I, Zakhartchouk A. SARS coronavirus protein 7a interacts with human Ap4A-hydrolase. Virol J. 2010; 7: 31.
110. Yuan X, Wu J, Shan Y, Yao Z, Dong B, Chen B et al. SARS coronavirus 7a protein blocks cell cycle progression at G0/G1 phase via the cyclin D3/pRb pathway. Virology. 2006; 346(1): 74-85.
111. Chen CY, Ping YH, Lee HC, Chen KH, Lee YM, Chan YJ et al. Open reading frame 8a of the human severe acute respiratory syndrome coronavirus not only promotes viral replication but also induces apoptosis. J Infect Dis. 2007; 196(3): 405-415.
112. Le TM, Wong HH, Tay FP, Fang S, Keng CT, Tan YJ et al. Expression, post-translational modification and biochemical characterization of proteins encoded by subgenomic mRNA8 of the severe acute respiratory syndrome coronavirus. FEBS J. 2007; 274(16): 4211-4222.
113. Yount B, Roberts RS, Sims AC, Deming D, Frieman MB, Sparks J et al. Severe acute respiratory syndrome coronavirus group-specific open reading frames encode nonessential functions for replication in cell cultures and mice. J Virol. 2005; 79(23): 14909-14922.
114. Chow SC, Ho CY, Tam TT, Wu C, Cheung T, Chan PK et al. Specific epitopes of the structural and hypothetical proteins elicit variable humoral responses in SARS patients. J Clin Pathol. 2006; 59(5): 468-476.
115. Sharma K, Akerstrom S, Sharma AK, Chow VT, Teow S, Abrenica B et al. SARS-CoV 9b protein diffuses into nucleus, undergoes active Crm1 mediated nucleocytoplasmic export and triggers apoptosis when retained in the nucleus. PLoS One. 2011; 6(5): e19436.
116. Kumar P, Gunalan V, Liu B, Chow VT, Druce J, Birch C et al. The nonstructural protein 8 (nsp8) of the SARS coronavirus interacts with its ORF6 accessory protein. Virology. 2007; 366(2): 293-303.
117. WHO. Severe Acute Respiratory Syndrome (SARS): Status of the Outbreak and Lessons for the Immediate Future. Geneva: WHO; 2003.
118. WHO. Cumulative number of reported suspect and probable cases (SARS). 2003 [cited 28 June 2013]; 31 December 2003: [Available from: http://www.who.int/csr/sars/country/table2004_04_21/en/index.html
119. Tsang KW, Ho PL, Ooi GC, Yee WK, Wang T, Chan-Yeung M et al. A cluster of cases of severe acute respiratory syndrome in Hong Kong. N Engl J Med. 2003; 348(20): 1977-1985.
120. Lee N, Hui D, Wu A, Chan P, Cameron P, Joynt GM et al. A major outbreak of severe acute respiratory syndrome in Hong Kong. N Engl J Med. 2003; 348(20): 1986-1994.
121. Li Y, Duan S, Yu IT, Wong TW. Multi-zone modeling of probable SARS virus transmission by airflow between flats in Block E, Amoy Gardens. Indoor Air. 2005; 15(2): 96-111.
122. Peiris JS, Chu CM, Cheng VC, Chan KS, Hung IF, Poon LL et al. Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: A prospective study. Lancet. 2003; 361(9371): 1767-1772.
123. Yu IT, Sung JJ. The epidemiology of the outbreak of severe acute respiratory syndrome (SARS) in Hong Kong-What we do know and what we don’t. Epidemiol Infect. 2004; 132(5): 781-786.
124. WHO. WHO Update 63. 2003 [cited; Available from: http://www.who.int/csr/don/2003_05_23/en/]
125. WHO. WHO Update 35. 2003 [cited; Available from: http://www.who.int/csr/don/2003_05_23/en/]
126. WHO. WHO Update 36. 2003.
127. WHO. WHO Update 37. 2003 [cited; Available from: http://www.who.int/entity/csr/sars/archive/2003_04_23/en]
128. WHO. WHO Update 87. 2003.
129. Hsieh YH, Chen CW, Hsu SB. SARS outbreak, Taiwan, 2003. Emerg Infect Dis. 2004; 10(2): 201-206.
130. CDC. Severe acute respiratory syndrome-Taiwan, 2003. MMWR2003; 52: 461-466.
131. WHO. WHO Update 96. 2003 [cited; Available from: http://www.who.int/csr/don/2003_07_05/en/]
132. Hsu LY, Lee CC, Green JA, Ang B, Paton NI, Lee L et al. Severe acute respiratory syndrome (SARS) in Singapore: Clinical features of index patient and initial contacts. Emerg Infect Dis. 2003; 9(6): 713-717.
133. Tan CC. SARS in Singapore-Key lessons from an epidemic. Ann Acad Med Singapore. 2006; 35(5): 345-349.
134. Gamage B, Moore D, Copes R, Yassi A, Bryce E. Protecting health care workers from SARS and other respiratory pathogens: A review of the infection control literature. Am J Infect Control. 2005; 33(2): 114-121.
135. Hui DS, Chan MC, Wu AK, Ng PC. Severe acute respiratory syndrome (SARS): Epidemiology and clinical features. Postgrad Med J. 2004; 80(945): 373-381.
136. Oh VM, Lim TK. Singapore’s experience of SARS. Clin Med. 2003; 3(5): 448-451.
137. WHO. WHO Update 70. 2003 [cited; Available from: http://www.who.int/entity/csr/don/2003_05_30a/en]
138. Poutanen SM, Low DE, Henry B, Finkelstein S, Rose D, Green K et al. Identification of severe acute respiratory syndrome in Canada. N Engl J Med. 2003; 348(20): 1995-2005.
139. Booth CM, Matukas LM, Tomlinson GA, Rachlis AR, Rose DB, Dwosh HA et al. Clinical features and short-term outcomes of 144 patients with SARS in the greater Toronto area. JAMA. 2003; 289(21): 2801-2809.
140. Loutfy MR, Wallington T, Rutledge T, Mederski B, Rose K, Kwolek S et al. Hospital preparedness and SARS. Emerg Infect Dis. 2004; 10(5): 771-776.
141. McDonald LC, Simor AE, Su IJ, Maloney S, Ofner M, Chen KT et al. SARS in healthcare facilities, Toronto and Taiwan. Emerg Infect Dis. 2004; 10(5): 777-781.
142. WHO. WHO Update 93. 2003 [cited; Available from: http://www.who.int/csr/don/2003_07_02/en/]
143. WHO. WHO update 41. 2003 [cited; Available from: http://www.who.int/csr/sarsarchive/2003_04_28/en/]
144. Donnelly CA, Fisher MC, Fraser C, Ghani AC, Riley S, Ferguson NM et al. Epidemiological and genetic analysis of severe acute respiratory syndrome. Lancet Infect Dis. 2004; 4(11): 672-683.
145. Chan-Yeung M, Yu WC. Outbreak of severe acute respiratory syndrome in Hong Kong Special Administrative Region: Case report. BMJ. 2003; 326(7394): 850-852.
146. Lee HK, Tso EY, Chau TN, Tsang OT, Choi KW, Lai TS. Asymptomatic severe acute respiratory syndrome-associated coronavirus infection. Emerg Infect Dis. 2003; 9(11): 1491-1492.
147. Chiu YC, Wu KL, Chou YP, Fong TV, Tsai TL, Kuo CM et al. Diarrhea in medical care workers with severe acute respiratory syndrome. J Clin Gastroenterol. 2004; 38(10): 880-882.
148. Choi KW, Chau TN, Tsang O, Tso E, Chiu MC, Tong WL et al. Outcomes and prognostic factors in 267 patients with severe acute respiratory syndrome in Hong Kong. Ann Intern Med. 2003; 139(9): 715-723.
149. Liang WN, Zhao T, Liu ZJ, Guan BY, He X, Liu M et al. Severe acute respiratory syndrome-Retrospect and lessons of 2004 outbreak in China. Biomed Environ Sci. 2006; 19(6): 445-451.
150. Shi X, Gong E, Gao D, Zhang B, Zheng J, Gao Z et al. Severe acute respiratory syndrome associated coronavirus is detected in intestinal tissues of fatal cases. Am J Gastroenterol. 2005; 100(1): 169-176.
151. Leung GM, Lim WW, Ho LM, Lam TH, Ghani AC, Donnelly CA et al. Seroprevalence of IgG antibodies to SARS-coronavirus in asymptomatic or subclinical population groups. Epidemiol Infect. 2006; 134(2): 211-221.
152. Che XY, Di B, Zhao GP, Wang YD, Qiu LW, Hao W et al. A patient with asymptomatic severe acute respiratory syndrome (SARS) and antigenemia from the 2003-2004 community outbreak of SARS in Guangzhou, China. Clin Infect Dis. 2006; 43(1): e1-e5.
153. Ho KY, Singh KS, Habib AG, Ong BK, Lim TK, Ooi EE et al. Mild illness associated with severe acute respiratory syndrome coronavirus infection: Lessons from a prospective seroepidemiologic study of health-care workers in a teaching hospital in Singapore. J Infect Dis. 2004; 189(4): 642-647.
154. Leung DT, van Maren WW, Chan FK, Chan WS, Lo AW, Ma CH et al. Extremely low exposure of a community to severe acute respiratory syndrome coronavirus: False seropositivity due to use of bacterially derived antigens. J Virol. 2006; 80(18): 8920-8928.
155. Wong RS, Wu A, To KF, Lee N, Lam CW, Wong CK et al. Haematological manifestations in patients with severe acute respiratory syndrome: Retrospective analysis. BMJ. 2003; 326(7403): 1358-1362.
156. Yang M, Ng MH, Li CK. Thrombocytopenia in patients with severe acute respiratory syndrome (review). Hematology. 2005; 10(2): 101-105.
157. Hui DS, Wong PC, Wang C. SARS: Clinical features and diagnosis. Respirology. 2003; 8 Suppl: S20-S24.
158. Hui DS. An overview on severe acute respiratory syndrome (SARS). Monaldi Arch Chest Dis. 2005; 63(3): 149-157.
159. Joynt GM, Antonio GE, Lam P, Wong KT, Li T, Gomersall CD et al. Late-stage adult respiratory distress syndrome caused by severe acute respiratory syndrome: Abnormal findings at thin-section CT. Radiology. 2004; 230(2): 339-346.
160. Lapinsky SE, Hawryluck L. ICU management of severe acute respiratory syndrome. Intensive Care Med. 2003; 29(6): 870-875.
161. Manocha S, Walley KR, Russell JA. Severe acute respiratory distress syndrome (SARS): A critical care perspective. Crit Care Med. 2003; 31(11): 2684-2692.
162. Bassetti S, Bischoff WE, Sherertz RJ. Are SARS superspreaders cloud adults? Emerg Infect Dis. 2005; 11(4): 637-638.
163. Masuda N, Konno N, Aihara K. Transmission of severe acute respiratory syndrome in dynamical small-world networks. Phys Rev E Stat Nonlin Soft Matter Phys. 2004; 69(3 Pt 1): 031917.
164. Che XY, Qiu LW, Pan YX, Wen K, Hao W, Zhang LY et al. Sensitive and specific monoclonal antibody-based capture enzyme immunoassay for detection of nucleocapsid antigen in sera from patients with severe acute respiratory syndrome. J Clin Microbiol. 2004; 42(6): 2629-2635.
165. Chen S, Lu D, Zhang M, Che J, Yin Z, Zhang S et al. Double-antigen sandwich ELISA for detection of antibodies to SARS-associated coronavirus in human serum. Eur J Clin Microbiol Infect Dis. 2005; 24(8): 549-553.
166. Di B, Hao W, Gao Y, Wang M, Wang YD, Qiu LW et al. Monoclonal antibody-based antigen capture enzyme-linked immunosorbent assay reveals high sensitivity of the nucleocapsid protein in acute-phase sera of severe acute respiratory syndrome patients. Clin Diagn Lab Immunol. 2005; 12(1): 135-140.
167. Gimenez LG, Rojas J, Rojas A, Mendoza J, Camacho AG. Development of an enzyme-linked immunosorbent assay-based test with a cocktail of nucleocapsid and spike proteins for detection of severe acute respiratory syndrome-associated coronavirus-specific antibody. Clin Vaccine Immunol. 2009; 16(2): 241-245.
168. Adachi D, Johnson G, Draker R, Ayers M, Mazzulli T, Talbot PJ et al. Comprehensive detection and identification of human coronaviruses, including the SARS-associated coronavirus, with a single RT-PCR assay. J Virol Methods. 2004; 122(1): 29-36.
169. Chan PK, To WK, Ng KC, Lam RK, Ng TK, Chan RC et al. Laboratory diagnosis of SARS. Emerg Infect Dis. 2004; 10(5): 825-831.
170. Drosten C, Chiu LL, Panning M, Leong HN, Preiser W, Tam JS et al. Evaluation of advanced reverse transcription-PCR assays and an alternative PCR target region for detection of severe acute respiratory syndrome-associated coronavirus. J Clin Microbiol. 2004; 42(5): 2043-2047.
171. Emery SL, Erdman DD, Bowen MD, Newton BR, Winchell JM, Meyer RF et al. Real-time reverse transcription-polymerase chain reaction assay for SARS-associated coronavirus. Emerg Infect Dis. 2004; 10(2): 311-316.
172. Antonio GE, Wong KT, Chu WC, Hui DS, Cheng FW, Yuen EH et al. Imaging in severe acute respiratory syndrome (SARS). Clin Radiol. 2003; 58(11): 825-832.
173. Wong KT, Antonio GE, Hui DS, Lee N, Yuen EH, Wu A et al. Severe acute respiratory syndrome: Radiographic appearances and pattern of progression in 138 patients. Radiology. 2003; 228(2): 401-406.
174. Antonio GE, Wong KT, Hui DS, Wu A, Lee N, Yuen EH et al. Thin-section CT in patients with severe acute respiratory syndrome following hospital discharge: Preliminary experience. Radiology. 2003; 228(3): 810-815.
175. Wong KT, Antonio GE, Hui DS, Lee N, Yuen EH, Wu A et al. Thin-section CT of severe acute respiratory syndrome: Evaluation of 73 patients exposed to or with the disease. Radiology. 2003; 228(2): 395-400.
176. Chau TN, Lee KC, Yao H, Tsang TY, Chow TC, Yeung YC et al. SARS-associated viral hepatitis caused by a novel coronavirus: Report of three cases. Hepatology. 2004; 39(2): 302-310.
177. Leung WK, To KF, Chan PK, Chan HL, Wu AK, Lee N et al. Enteric involvement of severe acute respiratory syndrome-associated coronavirus infection. Gastroenterology. 2003; 125(4): 1011-1017.
178. To KF, Tong JH, Chan PK, Au FW, Chim SS, Chan KC et al. Tissue and cellular tropism of the coronavirus associated with severe acute respiratory syndrome: An in-situ hybridization study of fatal cases. J Pathol. 2004; 202(2): 157-163.
179. Ding Y, He L, Zhang Q, Huang Z, Che X, Hou J et al. Organ distribution of severe acute respiratory syndrome (SARS) associated coronavirus (SARS-CoV) in SARS patients: Implications for pathogenesis and virus transmission pathways. J Pathol. 2004; 203(2): 622-630.
180. Tse GM, Hui PK, Ma TK, Lo AW, To KF, Chan WY et al. Sputum cytology of patients with severe acute respiratory syndrome (SARS). J Clin Pathol. 2004; 57(3): 256-259.
181. Gu J, Korteweg C. Pathology and pathogenesis of severe acute respiratory syndrome. Am J Pathol. 2007; 170(4): 1136-1147.
182. Hwang DM, Chamberlain DW, Poutanen SM, Low DE, Asa SL, Butany J. Pulmonary pathology of severe acute respiratory syndrome in Toronto. Mod Pathol. 2005; 18(1): 1-10.
183. Lang ZW, Zhang LJ, Zhang SJ, Meng X, Li JQ, Song CZ et al. A clinicopathological study of three cases of severe acute respiratory syndrome (SARS). Pathology. 2003; 35(6): 526-531.
184. Tse GM, To KF, Chan PK, Lo AW, Ng KC, Wu A et al. Pulmonary pathological features in coronavirus associated severe acute respiratory syndrome (SARS). J Clin Pathol. 2004; 57(3): 260-265.
185. Chen X, Zhou B, Li M, Liang X, Wang H, Yang G et al. Serology of severe acute respiratory syndrome: Implications for surveillance and outcome. J Infect Dis. 2004; 189(7): 1158-1163.
186. Dong BQ, Liu W, Fan XH, Vijaykrishna D, Tang XC, Gao F et al. Detection of a novel and highly divergent coronavirus from Asian leopard cats and Chinese ferret badgers in Southern China. J Virol. 2007; 81(13): 6920-6926.
187. Balboni A, Battilani M, Prosperi S. The SARS-like coronaviruses: The role of bats and evolutionary relationships with SARS coronavirus. New Microbiol. 2012; 35(1): 1-16.
188. Graham RL, Baric RS. Recombination, reservoirs, and the modular spike: Mechanisms of coronavirus cross-species transmission. J Virol. 2010; 84(7): 3134-3146.
189. Wong S, Lau S, Woo P, Yuen KY. Bats as a continuing source of emerging infections in humans. Rev Med Virol. 2007; 17(2): 67-91.
190. Wang LF, Eaton BT. Bats, civets and the emergence of SARS. Curr Top Microbiol Immunol. 2007; 315: 325-344.
191. Marzi A, Gramberg T, Simmons G, Moller P, Rennekamp AJ, Krumbiegel M et al. DC-SIGN and DC-SIGNR interact with the glycoprotein of Marburg virus and the S protein of severe acute respiratory syndrome coronavirus. J Virol. 2004; 78(21): 12090-12095.
192. Yang ZY, Huang Y, Ganesh L, Leung K, Kong WP, Schwartz O et al. pH-dependent entry of severe acute respiratory syndrome coronavirus is mediated by the spike glycoprotein and enhanced by dendritic cell transfer through DC-SIGN. J Virol. 2004; 78(11): 5642-5650.
193. Chen J, Lau YF, Lamirande EW, Paddock CD, Bartlett JH, Zaki SR et al. Cellular immune responses to severe acute respiratory syndrome coronavirus (SARS-CoV) infection in senescent BALB/c mice: CD4+ T cells are important in control of SARS-CoV infection. J Virol. 2010; 84(3): 1289-301.
194. Kuri T, Weber F. Interferon interplay helps tissue cells to cope with SARS-coronavirus infection. Virulence. 2010; 1(4): 273-275.
195. Tsang K, Seto WH. Severe acute respiratory syndrome: Scientific and anecdotal evidence for drug treatment. Curr Opin Investig Drugs. 2004; 5(2): 179-185.
196. Tai DY. Pharmacologic treatment of SARS: Current knowledge and recommendations. Ann Acad Med Singapore. 2007; 36(6): 438-443.
197. Wu W, Wang J, Liu P, Chen W, Yin S, Jiang S et al. A hospital outbreak of severe acute respiratory syndrome in Guangzhou, China. Chin Med J (Engl). 2003; 116(6): 811-818.
198. Stockman LJ, Bellamy R, Garner P. SARS: Systematic review of treatment effects. PLoS Med. 2006; 3(9): e343.
199. Cheng Y, Wong R, Soo YO, Wong WS, Lee CK, Ng MH et al. Use of convalescent plasma therapy in SARS patients in Hong Kong. Eur J Clin Microbiol Infect Dis. 2005; 24(1): 44-46.
200. Soo YO, Cheng Y, Wong R, Hui DS, Lee CK, Tsang KK et al. Retrospective comparison of convalescent plasma with continuing high-dose methylprednisolone treatment in SARS patients. Clin Microbiol Infect. 2004; 10(7): 676-678.
201. Zhao Z, Zhang F, Xu M, Huang K, Zhong W, Cai W et al. Description and clinical treatment of an early outbreak of severe acute respiratory syndrome (SARS) in Guangzhou, PR China. J Med Microbiol. 2003; 52(Pt 8): 715-720.
202. Lai ST. Treatment of severe acute respiratory syndrome. Eur J Clin Microbiol Infect Dis. 2005; 24(9): 583-591.
203. Chan MH, Chan PK, Griffith JF, Chan IH, Lit LC, Wong CK et al. Steroid-induced osteonecrosis in severe acute respiratory syndrome: A retrospective analysis of biochemical markers of bone metabolism and corticosteroid therapy. Pathology. 2006; 38(3): 229-235.
204. Roper RL, Rehm KE. SARS vaccines: Where are we? Expert Rev Vaccines. 2009; 8(7): 887-898.
205. Zheng BJ, Du LY, Zhao GY, Lin YP, Sui HY, Chan C et al. Studies of SARS virus vaccines. Hong Kong Med J. 2008; 14 Suppl 4: 39-43.
206. Enjuanes L, Dediego ML, Alvarez E, Deming D, Sheahan T, Baric R. Vaccines to prevent severe acute respiratory syndrome coronavirus-induced disease. Virus Res. 2008; 133(1): 45-62.
207. Du L, He Y, Jiang S, Zheng BJ. Development of subunit vaccines against severe acute respiratory syndrome. Drugs Today (Barc). 2008; 44(1): 63-73.
208. Pitzer VE, Leung GM, Lipsitch M. Estimating variability in the transmission of severe acute respiratory syndrome to household contacts in Hong Kong, China. Am J Epidemiol. 2007; 166(3): 355-363.
209. Lipsitch M, Cohen T, Cooper B, Robins JM, Ma S, James L et al. Transmission dynamics and control of severe acute respiratory syndrome. Science. 2003; 300(5627): 1966-1970.